Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shkreli Subpoenaed On Drug Prices, Refuses To Give Up Records

This article was originally published in Scrip

Executive Summary

Martin Shkreli, the former hedge-fund manager who recently lost his job as CEO at two drug companies after being arrested on fraud charges, has been subpoenaed by the House Oversight and Government Reform Committee to testify at a Jan. 26 hearing focused on the increases in the prices of older medicines – like the 5,000% spike in the cost for the toxoplasmosis drug Daraprim (pyrimethamine), which is sold by Turing Pharmaceuticals Inc., one of the firms he started and then was booted from.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts